Stay updated with breaking news from Biocon ceo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
"Every one of our individual businesses is at an inflection point of high growth. Peter Bains, who is a veteran when it comes to the pharma and biopharma industry in terms of his global experience, also understands the Biocon Group because he has basically played a very key role in Syngene. Through Syngene, he has understood the entire Biocon business very well." ....
"Peter, who is a veteran when it comes to the pharma and biopharma industry in terms of his global experience, also understands the Biocon Group because he has basically played a very key role in Syngene. Through Syngene, he has understood the entire Biocon business very well." ....
He has over 30 years of global experience in strategic and operational leadership, including at board, CEO and senior corporate levels. He served as CEO and on the Board of Syngene International Ltd, a subsidiary of the company, for almost 6 years from 2010, and led the company to its successful public listing in 2015, Biocon said. ....
Biosimilars have led the growth in the April-June 2023 period and will continue to do so. The company also hopes to capitalise on its already strong presence in the US market, and stay ahead of the competition in the Indian market. ....